The MSCI China Health Care Index has already snowballed by 31.7% YTD, outpacing the MSCI China Index by 18.2%, according to a report from CMBI. Due to the market's high expectations for the frequency and scale of overseas transactions, it is expected that the industry may still face some pullback pressure in the short term.

CMBI urged in its report attention to the consumer healthcare sector, given that some companies in this sector had solid fundamentals and reasonable valuations, making them worthy of investment. The broker's core recommended targets included GIANT BIOGENE (02367.HK)  -3.500 (-6.494%)    Short selling $119.87M; Ratio 15.070%   , ANGELALIGN (06699.HK)  +0.150 (+0.260%)    Short selling $371.22K; Ratio 3.536%   , and GUSHENGTANG (02273.HK)  -0.250 (-0.736%)    Short selling $1.23M; Ratio 5.912%   .

Related NewsBOCOMI Ratings, TPs on Pharmas (Table)
Meanwhile, the fundamentals of the pharma industry remained vigorous with valuations within a reasonable range, even though the innovative drug sector may continue to pull back in the short term due to profit-taking and other factors. CMBI recommended buying 3 3SBIO (01530.HK)  -0.150 (-0.662%)    Short selling $69.77M; Ratio 16.360%   , BEIGENE (06160.HK)  +1.700 (+1.057%)    Short selling $77.18M; Ratio 21.500%   (ONC.US)      , INNOVENT BIO (01801.HK)  +0.150 (+0.183%)    Short selling $98.96M; Ratio 13.040%   , GIANT BIOGENE, ANGELALIGN, and GUSHENGTANG.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-06-25 12:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)